News & Insights

Cases & Deals

July 20, 2016

King & Spalding Advises Jounce Therapeutics on Deal Worth Up to $2.5 Billion

SAN FRANCISCO, July 20, 2016 — King & Spalding advised Jounce Therapeutics on a strategic collaboration with Celgene Corp. for the development and commercialization of innovative, immuno-oncology treatments for patients with cancer.

Under the terms of the collaboration, announced yesterday, Celgene will make an upfront payment to Jounce of $225 million. Jounce will also receive regulatory, development and net sales milestone payments as well as tiered royalties on sales outside the United States and will share profits within the United States. Aggregate payments for development, regulatory and commercial milestones could potentially be $2.3 billion in total across all programs reaching commercialization.

The King & Spalding team included San Francisco-based partner Tom Duley and senior associate Stephen Abreu, both of whom are corporate lawyers focused on the life sciences industry. Additional assistance was provided by partners Elaine Tseng, Jonathan Talansky, Peter Todaro and Laura Bushnell.

About King & Spalding
Celebrating more than 130 years of service, King & Spalding is an international law firm that represents a broad array of clients, including half of the Fortune Global 100, with more than 900 lawyers in 18 offices in the United States, Europe, the Middle East and Asia. The firm has handled matters in over 160 countries on six continents and is consistently recognized for the results it obtains, uncompromising commitment to quality, and dedication to understanding the business and culture of its clients. More information is available at